Blennow K - Search Results

1

Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study.

Lista S, Toschi N, Baldacci F, Zetterberg H, Blennow K, Kilimann I, Teipel SJ, Cavedo E, Dos Santos AM, Epelbaum S, Lamari F, Dubois B, Nisticò R, Floris R, Garaci F, Hampel H; Alzheimer Precision Medicine Initiative (APMI). Lista S, et al. Among authors: blennow k. J Alzheimers Dis. 2017;59(4):1327-1334. doi: 10.3233/JAD-170368. J Alzheimers Dis. 2017. PMID: 28731449

2

Monoamine metabolites in cerebrospinal fluid and behavioral ratings in patients with early and late onset of Alzheimer dementia.

Bråne G, Gottfries CG, Blennow K, Karlsson I, Lekman A, Parnetti L, Svennerholm L, Wallin A. Bråne G, et al. Among authors: blennow k. Alzheimer Dis Assoc Disord. 1989 Fall;3(3):148-56. doi: 10.1097/00002093-198903030-00004. Alzheimer Dis Assoc Disord. 1989. PMID: 2477044

3

Ubiquitin in cerebrospinal fluid in Alzheimer's disease and vascular dementia.

Blennow K, Davidsson P, Wallin A, Gottfries CG, Svennerholm L. Blennow K, et al. Int Psychogeriatr. 1994 Spring;6(1):13-22; discussion 59-60. doi: 10.1017/s1041610294001584. Int Psychogeriatr. 1994. PMID: 8054491

4

Reduction of chromogranin A and B but not C in the cerebrospinal fluid in subjects with schizophrenia.

Landén M, Grenfeldt B, Davidsson P, Stridsberg M, Regland B, Gottfries CG, Blennow K. Landén M, et al. Among authors: blennow k. Eur Neuropsychopharmacol. 1999 Jun;9(4):311-5. doi: 10.1016/s0924-977x(98)00042-x. Eur Neuropsychopharmacol. 1999. PMID: 10422891

5

Cerebrospinal fluid markers of pathogenetic processes in vascular dementia, with special reference to the subcortical subtype.

Wallin A, Blennow K, Rosengren L. Wallin A, et al. Among authors: blennow k. Alzheimer Dis Assoc Disord. 1999 Oct-Dec;13 Suppl 3:S102-5. Alzheimer Dis Assoc Disord. 1999. PMID: 10609688 Review.

6

Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke.

Hesse C, Rosengren L, Andreasen N, Davidsson P, Vanderstichele H, Vanmechelen E, Blennow K. Hesse C, et al. Among authors: blennow k. Neurosci Lett. 2001 Jan 19;297(3):187-90. doi: 10.1016/s0304-3940(00)01697-9. Neurosci Lett. 2001. PMID: 11137759 Clinical Trial.

7

CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease.

Blennow K, Vanmechelen E, Hampel H. Blennow K, et al. Mol Neurobiol. 2001 Aug-Dec;24(1-3):87-97. doi: 10.1385/MN:24:1-3:087. Mol Neurobiol. 2001. PMID: 11831556 Review.

8

Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms.

Sjögren M, Davidsson P, Wallin A, Granérus AK, Grundström E, Askmark H, Vanmechelen E, Blennow K. Sjögren M, et al. Among authors: blennow k. Dement Geriatr Cogn Disord. 2002;13(2):112-8. doi: 10.1159/000048642. Dement Geriatr Cogn Disord. 2002. PMID: 11844893

9

Beta-amyloid (Abeta) protein in cerebrospinal fluid as a biomarker for Alzheimer's disease.

Andreasen N, Blennow K. Andreasen N, et al. Among authors: blennow k. Peptides. 2002 Jul;23(7):1205-14. doi: 10.1016/s0196-9781(02)00056-6. Peptides. 2002. PMID: 12128078 Review.

10

Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.

Buerger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H, Blennow K, Andreasen N, Hofmann-Kiefer K, DeBernardis J, Kerkman D, McCulloch C, Kohnken R, Padberg F, Pirttilä T, Schapiro MB, Rapoport SI, Möller HJ, Davies P, Hampel H. Buerger K, et al. Among authors: blennow k. Arch Neurol. 2002 Aug;59(8):1267-72. doi: 10.1001/archneur.59.8.1267. Arch Neurol. 2002. PMID: 12164722 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,087 results

Search Page